




ENGOT-Cx7 / NSGO / MaRuC

Sponsor: NSGO



A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer


ENGOT-CX7 / NSGO / MaRuC

Participating groups:

- BGOG, Belgium
- CEEGOG, Czech Rep, Hungary, Ukraine
- NCRI, UK
- NOGGO, Germany
- PGOG, Poland
- PMHC, Canada

Study Status

- Submissions under way
- Expected FPI: Q1 2019



Stratification factors

- Histology (squamous vs adenosquamous, adenocarcinoma)
- FIGO stage & nodal status (2B vs 3-4 vs paraortic nodes)

Enrolment of patients with squamous cell histology will be capped once 60% patients with this histo-type are enrolled